Table_1.xls (9.5 kB)

Markov model input variables (all costs are in US dollars for the year 2013).

Download (0 kB)
posted on 18.04.2014 by Johannes Pfeil, Steffen Borrmann, Yeşim Tozan

DP = Dihydroartemisinin Piperaquine; AL = Artemether-Lumefantrine; SD = Standard Deviation; Max = Maximum; Min = Minimum.


Using the data reported by a multi-centre trial of ACTs on the number of patients whose treatment was failure free (N) over a follow-up period of 63 days [6], the weekly hazard rates for recurrent malaria following treatment with DHPQ and AL were estimated using Kaplan-Meier estimator as ht = 1−(Nt/Nt-1), where t = 1, 2,…9 weeks. The hazard rate for uncomplicated malarial disease in healthy children was estimated by taking the average of the hazard rates for recurrent malaria at weeks 8 and 9 following treatment with DP and AL.


For these clinical outcomes, β distributions were calculated based on the incidence of mortality and neurological sequelae in malaria patients as reported in a randomized trail that compared parental treatment with either artesunate or quinine in African children with severe malaria [15], [16].